![Byong Kim](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Byong Kim
Direktör/Styrelseledamot på
LIPELLA PHARMACEUTICALS INC.
Förmögenhet: - $ per 2026-06-30
Profil
Byong Kim currently works at Lipella Pharmaceuticals, Inc., as Independent Director from 2022, CytoReason Ltd., as Independent Director, and Bridge Biotherapeutics, Inc., as Director & Executive Vice President from 2016.
Dr. Kim also formerly worked at Novartis Institutes for Biomedical Research, Inc., as Associate Director, Alkermes, Inc., as Principal, and Oxford Bioscience Partners, as Entrepreneur-in-Residence.
Dr. Kim received his Masters Business Admin degree from Carnegie Mellon University, doctorate degree from The University of Texas at Austin, and undergraduate degree from the University of California, Irvine.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2025-03-26 | 0 ( -.--% ) | - $ | 2026-06-30 |
Aktiva positioner av Byong Kim
| Företag | Position | Start |
|---|---|---|
| LIPELLA PHARMACEUTICALS INC. | Direktör/Styrelseledamot | 2022-03-01 |
| PARATAXIS KOREA, INC. | Direktör/Styrelseledamot | 2016-01-01 |
CytoReason Ltd.
 CytoReason Ltd. Information Technology ServicesTechnology Services Operates an artificial intelligence that develop computational model of the human body, accurate enough to start replacing animal and human trials in drug | Direktör/Styrelseledamot | - |
Tidigare kända positioner av Byong Kim
| Företag | Position | Slut |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Företagsledare/Principal | - |
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Företagsledare/Principal | - |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Privat kapitalinvesterare | - |
Byong Kims utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
5
Första gradens relationer
9
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 9 |
|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Health Technology |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lipella Pharmaceuticals, Inc.
 Lipella Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes lipid-based therapies for common bladder syndromes | Health Technology |
The University of Texas at Austin
 The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Bridge Biotherapeutics, Inc.
 Bridge Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and biological products | Health Technology |
CytoReason Ltd.
CytoReason Ltd. Information Technology ServicesTechnology Services Operates an artificial intelligence that develop computational model of the human body, accurate enough to start replacing animal and human trials in drug | Technology Services |
